About Gufic Biosciences Limited
Data last updated: 25 May 2026
Gufic Biosciences Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 23 July 1984, the company has been in operation for over 42 years.
Registered with ROC Mumbai under CIN L24100MH1984PLC033519. Listed on BSE: 509079 and NSE: GUFICBIO.
Capital: an authorised share capital of ₹85.75 Cr and a paid-up capital of ₹10.03 Cr. Formerly known as Central Leasing Limited. It is led by directors including Akshya Kumar Mahapatra and Pankaj Jayakumar Gandhi.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Shop – 37 First Floor Kamala Bhavan Ii S Nityanand Road Andheri East, Mumbai, Maharashtra, India – 400069.
As per the financials filed for FY 2025, the company reported a revenue of ₹823.43 Cr, a growth of 2% compared to the previous year.
The company has a workforce of approximately 1,362 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Gufic Group. As per MCA filings, the company has open charges of ₹604.84 Cr and satisfied charges of ₹201.8 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gufic.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressShop – 37 First Floor Kamala Bhavan Ii S Nityanand Road Andheri East, Mumbai, Maharashtra, India – 400069
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Gufic Biosciences Limited
Gufic Biosciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100MH1984PLC033519, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100MH1984PLC033519 | Current |
| L65990MH1901PLC033519 | Previous |
| L65990MH1984PLC033519 | Previous |
Associated Brands with Gufic Biosciences Limited
Gufic Biosciences Limited operates one associated brand: Gufic Group. These brands represent Gufic Biosciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Lyophilized injections and pharmaceutical products are manufactured across therapeutic segments. | gufic.com |
Business Activity of Gufic Biosciences Limited
Gufic Biosciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Gufic Biosciences Limited
Gufic Biosciences Limited is audited by M/s. Mittal Agarwal & Company (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s. Mittal Agarwal & Company (ICAI peer reviewed, certificate valid till 2028-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Gufic Biosciences Limited
Gufic Biosciences Limited is currently managed by 8 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Akshya Kumar Mahapatra | Director | 14 Nov 2024 | 1 Years 7 Months | Current |
|
Pankaj Jayakumar Gandhi
Also directs:
Gufic Biosciences Limited, Gufic Chem Private Limited, Gufic Private Limited and 2 more
|
Whole-Time Director | 01 Aug 2013 | 12 Years 11 Months | Current |
| Jayesh Pannalal Choksi | Managing Director | 31 Aug 1999 | 26 Years 10 Months | Current |
| Pranav Jayesh Choksi | Whole-Time Director | 25 Jun 2004 | 22 Years 0 Months | Current |
| Kamal Kishore Seth | Director | 27 Jun 2024 | 2 Years 0 Months | Current |
|
Anu Sanjiv Aurora
Also directs:
Gufic Biosciences Limited
|
Director | 23 Dec 2019 | 6 Years 6 Months | Current |
Financials of Gufic Biosciences Limited FY 2026 filings available
Gufic Biosciences Limited reported revenue of ₹944.01 Cr (up 15.15% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹944.01 Cr | ₹819.81 Cr | ₹806.67 Cr |
| Other Income | ₹2.66 Cr | ₹3.63 Cr | ₹2.18 Cr |
| Total Income | ₹946.66 Cr | ₹823.43 Cr | ₹808.84 Cr |
| Cost of Materials Consumed | ₹425.33 Cr | ₹344.2 Cr | ₹341.32 Cr |
| Purchases of Stock-in-Trade | ₹64.71 Cr | ₹55.41 Cr | ₹58.06 Cr |
| Changes in Inventories | -₹68.86 Cr | -₹24.91 Cr | -₹9.49 Cr |
| Employee Benefit Expense | ₹151.68 Cr | ₹127.05 Cr | ₹109.63 Cr |
| Finance Costs | ₹36.61 Cr | ₹23.11 Cr | ₹15.36 Cr |
| Depreciation & Amortisation | ₹30.83 Cr | ₹21.06 Cr | ₹17.02 Cr |
| Other Expenses | ₹219.81 Cr | ₹183.36 Cr | ₹161.27 Cr |
| Total Expenses | ₹860.12 Cr | ₹729.29 Cr | ₹693.17 Cr |
| Profit Before Exceptional Items & Tax | ₹86.55 Cr | ₹94.14 Cr | ₹115.67 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹86.55 Cr | ₹94.14 Cr | ₹115.67 Cr |
| Total Tax Expense | ₹22.34 Cr | ₹24.49 Cr | ₹29.54 Cr |
| Net Profit | ₹64.21 Cr | ₹69.65 Cr | ₹86.14 Cr |
| attributable to Owners | ₹0 | ₹0 | - |
| attributable to NCI | -₹20,000 | -₹8,000 | - |
| Other Comprehensive Income | ₹49.93 Lakh | -₹12.77 Lakh | -₹40.39 Lakh |
| Total Comprehensive Income | ₹64.71 Cr | ₹69.52 Cr | ₹85.73 Cr |
| EBITDA (computed) | ₹153.99 Cr | ₹138.32 Cr | ₹148.05 Cr |
| Basic EPS | ₹6.40 | ₹6.95 | ₹8.74 |
| Diluted EPS | ₹6.40 | ₹6.95 | ₹8.74 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹1,342.37 Cr | ₹1,169.36 Cr | ₹1,092.54 Cr |
| Non-current Assets | ₹540.26 Cr | ₹544.84 Cr | ₹492.06 Cr |
| Current Assets | ₹802.12 Cr | ₹624.52 Cr | ₹600.48 Cr |
| Property, Plant & Equipment | ₹484.85 Cr | ₹499.65 Cr | ₹153.27 Cr |
| Inventories | ₹324.47 Cr | ₹216.87 Cr | ₹200.48 Cr |
| Trade Receivables | ₹297.4 Cr | ₹314.61 Cr | ₹329.94 Cr |
| Cash & Equivalents | ₹62.19 Cr | ₹15.72 Cr | ₹1.14 Cr |
| Equity (Net Worth) | ₹664.99 Cr | ₹601.08 Cr | ₹532.56 Cr |
| Equity Share Capital | ₹10.03 Cr | ₹10.03 Cr | ₹10.03 Cr |
| Borrowings (Non-current) | ₹105.04 Cr | ₹130.5 Cr | ₹153.96 Cr |
| Borrowings (Current) | ₹280.13 Cr | ₹179.88 Cr | ₹163.07 Cr |
| Total Debt (computed) | ₹385.16 Cr | ₹310.37 Cr | ₹317.03 Cr |
| Current Liabilities | ₹517.85 Cr | ₹387.56 Cr | ₹372.05 Cr |
| Total Liabilities | ₹677.39 Cr | ₹568.29 Cr | ₹559.98 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | ₹44.97 Cr | ₹122.57 Cr | -₹7.46 Cr |
| Investing Cash Flow | -₹30.96 Cr | -₹70.78 Cr | -₹102.39 Cr |
| Financing Cash Flow | ₹32.46 Cr | -₹37.2 Cr | ₹82.38 Cr |
| Capital Expenditure | ₹31.18 Cr | ₹75.53 Cr | ₹112.69 Cr |
| Free Cash Flow (computed) | ₹13.79 Cr | ₹47.04 Cr | -₹120.15 Cr |
| Dividends Paid | ₹1 Cr | ₹1 Cr | ₹96.94 Lakh |
| Net Change in Cash | ₹46.46 Cr | ₹14.59 Cr | -₹27.47 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹251.82 Cr | ₹231.41 Cr | ₹237.05 Cr | ₹223.72 Cr | ₹205.02 Cr | ₹207.79 Cr | ₹204.18 Cr | ₹202.81 Cr | ₹194.99 Cr | ₹201.78 Cr | ₹214.87 Cr |
| Other Income | -₹1.17 Cr | ₹79.05 Lakh | ₹2.12 Cr | ₹92.52 Lakh | ₹39.45 Lakh | ₹1.86 Cr | ₹11.38 Lakh | ₹1.25 Cr | ₹88.14 Lakh | ₹42.36 Lakh | ₹33.44 Lakh |
| Total Income | ₹250.65 Cr | ₹232.2 Cr | ₹239.17 Cr | ₹224.65 Cr | ₹205.41 Cr | ₹209.66 Cr | ₹204.29 Cr | ₹204.07 Cr | ₹195.87 Cr | ₹202.2 Cr | ₹215.21 Cr |
| Cost of Materials Consumed | ₹124.07 Cr | ₹99.27 Cr | ₹113.47 Cr | ₹88.52 Cr | ₹122.91 Cr | ₹73.59 Cr | ₹74.93 Cr | ₹72.77 Cr | ₹90.95 Cr | ₹72.92 Cr | ₹95.29 Cr |
| Purchases of Stock-in-Trade | ₹8.93 Cr | ₹15.82 Cr | ₹25.69 Cr | ₹14.27 Cr | ₹10.85 Cr | ₹15.55 Cr | ₹16.57 Cr | ₹12.45 Cr | ₹14.34 Cr | ₹12 Cr | ₹15.66 Cr |
| Changes in Inventories | -₹18.06 Cr | -₹14.07 Cr | -₹34.72 Cr | -₹2.01 Cr | -₹44.09 Cr | ₹5.03 Cr | ₹4.62 Cr | ₹9.53 Cr | -₹16.68 Cr | ₹10.41 Cr | -₹1.84 Cr |
| Employee Benefit Expense | ₹38.14 Cr | ₹40.09 Cr | ₹37.45 Cr | ₹36 Cr | ₹35.57 Cr | ₹33.96 Cr | ₹28.47 Cr | ₹29.05 Cr | ₹29.6 Cr | ₹30.6 Cr | ₹26.78 Cr |
| Finance Costs | ₹9.44 Cr | ₹8.36 Cr | ₹9.58 Cr | ₹9.23 Cr | ₹8.4 Cr | ₹4.91 Cr | ₹5.18 Cr | ₹4.62 Cr | ₹3.65 Cr | ₹3.18 Cr | ₹4.46 Cr |
| Depreciation & Amortisation | ₹7.65 Cr | ₹7.69 Cr | ₹7.77 Cr | ₹7.72 Cr | ₹7.84 Cr | ₹4.62 Cr | ₹4.3 Cr | ₹4.31 Cr | ₹4.34 Cr | ₹4.14 Cr | ₹4.3 Cr |
| Other Expenses | ₹51.52 Cr | ₹57.32 Cr | ₹57.32 Cr | ₹53.65 Cr | ₹53.4 Cr | ₹45.75 Cr | ₹40.96 Cr | ₹43.25 Cr | ₹42.55 Cr | ₹39.38 Cr | ₹39.62 Cr |
| Total Expenses | ₹221.7 Cr | ₹214.48 Cr | ₹216.57 Cr | ₹207.37 Cr | ₹194.89 Cr | ₹183.4 Cr | ₹175.04 Cr | ₹175.96 Cr | ₹168.76 Cr | ₹172.64 Cr | ₹184.26 Cr |
| Profit Before Exceptional Items & Tax | ₹28.95 Cr | ₹17.72 Cr | ₹22.6 Cr | ₹17.27 Cr | ₹10.52 Cr | ₹26.26 Cr | ₹29.25 Cr | ₹28.1 Cr | ₹27.12 Cr | ₹29.56 Cr | ₹30.95 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹28.95 Cr | ₹17.72 Cr | ₹22.6 Cr | ₹17.27 Cr | ₹10.52 Cr | ₹26.26 Cr | ₹29.25 Cr | ₹28.1 Cr | ₹27.12 Cr | ₹29.56 Cr | ₹30.95 Cr |
| Total Tax Expense | ₹7.05 Cr | ₹5.3 Cr | ₹5.78 Cr | ₹4.2 Cr | ₹2.81 Cr | ₹6.96 Cr | ₹7.49 Cr | ₹7.25 Cr | ₹7.07 Cr | ₹7.3 Cr | ₹7.74 Cr |
| Net Profit | ₹21.9 Cr | ₹12.42 Cr | ₹16.82 Cr | ₹13.07 Cr | ₹7.72 Cr | ₹19.31 Cr | ₹21.77 Cr | ₹20.86 Cr | ₹20.05 Cr | ₹22.26 Cr | ₹23.21 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - | - | - |
| attributable to NCI | ₹0 | ₹0 | -₹14,000 | ₹0 | ₹0 | -₹1,000 | -₹6,000 | -₹1,000 | - | - | - |
| Other Comprehensive Income | ₹49.93 Lakh | ₹0 | ₹0 | ₹0 | -₹12.77 Lakh | ₹0 | ₹0 | ₹0 | -₹40.39 Lakh | ₹0 | ₹0 |
| Total Comprehensive Income | ₹22.4 Cr | ₹12.42 Cr | ₹16.82 Cr | ₹13.07 Cr | ₹7.59 Cr | ₹19.31 Cr | ₹21.77 Cr | ₹20.86 Cr | ₹19.64 Cr | ₹22.26 Cr | ₹23.21 Cr |
| EBITDA (computed) | ₹46.04 Cr | ₹33.77 Cr | ₹39.96 Cr | ₹34.23 Cr | ₹26.77 Cr | ₹35.79 Cr | ₹38.73 Cr | ₹37.03 Cr | ₹35.11 Cr | ₹36.88 Cr | ₹39.7 Cr |
| Basic EPS | ₹2.18 | ₹1.24 | ₹1.68 | ₹1.30 | ₹0.77 | ₹1.93 | ₹2.17 | ₹2.08 | ₹2.00 | ₹2.23 | ₹2.39 |
| Diluted EPS | ₹2.18 | ₹1.24 | ₹1.68 | ₹1.30 | ₹0.77 | ₹1.93 | ₹2.17 | ₹2.08 | ₹2.00 | ₹2.23 | ₹2.39 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹940.48 Cr | ₹819.81 Cr | ₹806.67 Cr | ₹690.62 Cr | ₹779.16 Cr | ₹487.7 Cr | ₹357.75 Cr |
| Other Income | ₹2.58 Cr | ₹3.62 Cr | ₹2.18 Cr | ₹2.57 Cr | ₹3.1 Cr | ₹3.73 Cr | ₹6.82 Cr |
| Total Income | ₹943.06 Cr | ₹823.42 Cr | ₹808.84 Cr | ₹693.19 Cr | ₹782.26 Cr | ₹491.43 Cr | ₹364.57 Cr |
| Cost of Materials Consumed | ₹425.33 Cr | ₹344.2 Cr | ₹341.32 Cr | ₹339.36 Cr | ₹353.93 Cr | ₹213.45 Cr | ₹152.98 Cr |
| Purchases of Stock-in-Trade | ₹64.73 Cr | ₹55.41 Cr | ₹58.06 Cr | ₹25.84 Cr | ₹77.42 Cr | ₹22.55 Cr | ₹37.22 Cr |
| Changes in Inventories | -₹68.86 Cr | -₹24.91 Cr | -₹9.49 Cr | -₹33.39 Cr | -₹19.39 Cr | ₹14.29 Cr | -₹12.73 Cr |
| Employee Benefit Expense | ₹151.68 Cr | ₹127.05 Cr | ₹109.63 Cr | ₹86.73 Cr | ₹85.61 Cr | ₹66.22 Cr | ₹51.57 Cr |
| Finance Costs | ₹36.61 Cr | ₹23.11 Cr | ₹15.36 Cr | ₹8.22 Cr | ₹4.85 Cr | ₹13.63 Cr | ₹12.72 Cr |
| Depreciation & Amortisation | ₹30.83 Cr | ₹21.06 Cr | ₹17.02 Cr | ₹22.28 Cr | ₹17.13 Cr | ₹16.31 Cr | ₹8.35 Cr |
| Other Expenses | ₹217.25 Cr | ₹183.07 Cr | ₹161.27 Cr | ₹137.42 Cr | ₹135.87 Cr | ₹87.27 Cr | ₹84.12 Cr |
| Total Expenses | ₹857.57 Cr | ₹728.99 Cr | ₹693.17 Cr | ₹586.47 Cr | ₹655.42 Cr | ₹433.72 Cr | ₹334.24 Cr |
| Profit Before Exceptional Items & Tax | ₹85.49 Cr | ₹94.43 Cr | ₹115.67 Cr | ₹106.72 Cr | ₹126.84 Cr | ₹57.71 Cr | ₹30.33 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹85.49 Cr | ₹94.43 Cr | ₹115.67 Cr | ₹106.72 Cr | ₹126.84 Cr | ₹57.71 Cr | ₹30.33 Cr |
| Total Tax Expense | ₹22.34 Cr | ₹24.49 Cr | ₹29.54 Cr | ₹27.02 Cr | ₹31 Cr | ₹13.48 Cr | ₹7.47 Cr |
| Net Profit | ₹63.15 Cr | ₹69.93 Cr | ₹86.14 Cr | ₹79.7 Cr | ₹95.84 Cr | ₹44.23 Cr | ₹22.86 Cr |
| Other Comprehensive Income | ₹49.93 Lakh | -₹12.77 Lakh | -₹40.39 Lakh | -₹53,000 | -₹44.06 Lakh | ₹27.1 Lakh | -₹1.98 Cr |
| Total Comprehensive Income | ₹63.65 Cr | ₹69.81 Cr | ₹85.73 Cr | ₹79.7 Cr | ₹95.4 Cr | ₹44.5 Cr | ₹20.88 Cr |
| EBITDA (computed) | ₹152.93 Cr | ₹138.6 Cr | ₹148.05 Cr | ₹137.23 Cr | ₹148.82 Cr | ₹87.65 Cr | ₹51.4 Cr |
| Basic EPS | ₹6.30 | ₹6.97 | ₹8.74 | ₹8.22 | ₹9.89 | ₹4.56 | ₹2.94 |
| Diluted EPS | ₹6.30 | ₹6.97 | ₹8.74 | ₹8.22 | ₹9.89 | ₹4.56 | ₹2.94 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,341.59 Cr | ₹1,169.63 Cr | ₹1,092.54 Cr | ₹861.16 Cr |
| Non-current Assets | ₹541.33 Cr | ₹545.85 Cr | ₹492.07 Cr | ₹397.05 Cr |
| Current Assets | ₹800.26 Cr | ₹623.78 Cr | ₹600.47 Cr | ₹464.11 Cr |
| Property, Plant & Equipment | ₹484.85 Cr | ₹499.65 Cr | ₹153.27 Cr | ₹158.89 Cr |
| Inventories | ₹324.47 Cr | ₹216.87 Cr | ₹200.48 Cr | ₹183.46 Cr |
| Trade Receivables | ₹297.4 Cr | ₹314.61 Cr | ₹329.94 Cr | ₹205.47 Cr |
| Cash & Equivalents | ₹60.32 Cr | ₹14.91 Cr | ₹1.13 Cr | ₹28.6 Cr |
| Equity (Net Worth) | ₹664.18 Cr | ₹601.36 Cr | ₹532.56 Cr | ₹347.81 Cr |
| Equity Share Capital | ₹10.03 Cr | ₹10.03 Cr | ₹10.03 Cr | ₹9.69 Cr |
| Borrowings (Non-current) | ₹105.04 Cr | ₹130.5 Cr | ₹153.96 Cr | ₹190.68 Cr |
| Borrowings (Current) | ₹280.13 Cr | ₹179.88 Cr | ₹163.07 Cr | ₹120.73 Cr |
| Total Debt (computed) | ₹385.16 Cr | ₹310.37 Cr | ₹317.03 Cr | ₹311.41 Cr |
| Current Liabilities | ₹517.87 Cr | ₹387.53 Cr | ₹372.05 Cr | ₹288.21 Cr |
| Total Liabilities | ₹677.41 Cr | ₹568.26 Cr | ₹559.98 Cr | ₹513.35 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹44.02 Cr | ₹122.78 Cr | -₹7.46 Cr | -₹26.59 Cr | ₹104.44 Cr |
| Investing Cash Flow | -₹30.96 Cr | -₹71.79 Cr | -₹102.4 Cr | -₹190.73 Cr | -₹95.94 Cr |
| Financing Cash Flow | ₹32.36 Cr | -₹37.2 Cr | ₹82.38 Cr | ₹234.31 Cr | -₹3.1 Cr |
| Capital Expenditure | ₹31.18 Cr | ₹75.52 Cr | ₹112.69 Cr | ₹187.6 Cr | ₹88.8 Cr |
| Free Cash Flow (computed) | ₹12.84 Cr | ₹47.25 Cr | -₹120.15 Cr | -₹214.19 Cr | ₹15.64 Cr |
| Dividends Paid | ₹1 Cr | ₹1 Cr | ₹96.94 Lakh | ₹1.04 Cr | ₹92.11 Lakh |
| Net Change in Cash | ₹45.42 Cr | ₹13.78 Cr | -₹27.48 Cr | ₹16.99 Cr | ₹5.41 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹252.05 Cr | ₹231.09 Cr | ₹230.42 Cr | ₹226.91 Cr | ₹205.02 Cr | ₹207.79 Cr | ₹204.18 Cr | ₹202.81 Cr | ₹194.99 Cr | ₹201.78 Cr | ₹214.87 Cr | ₹195.02 Cr |
| Other Income | -₹1.2 Cr | ₹79.32 Lakh | ₹2.09 Cr | ₹89.42 Lakh | ₹38.3 Lakh | ₹1.86 Cr | ₹11.38 Lakh | ₹1.25 Cr | ₹88.14 Lakh | ₹42.36 Lakh | ₹33.44 Lakh | ₹88.12 Lakh |
| Total Income | ₹250.86 Cr | ₹231.89 Cr | ₹232.51 Cr | ₹227.81 Cr | ₹205.4 Cr | ₹209.66 Cr | ₹204.29 Cr | ₹204.07 Cr | ₹195.87 Cr | ₹202.2 Cr | ₹215.21 Cr | ₹195.9 Cr |
| Cost of Materials Consumed | ₹124.27 Cr | ₹99.07 Cr | ₹113.47 Cr | ₹88.52 Cr | ₹122.91 Cr | ₹73.59 Cr | ₹74.93 Cr | ₹72.77 Cr | ₹90.95 Cr | ₹72.92 Cr | ₹95.29 Cr | ₹80.38 Cr |
| Purchases of Stock-in-Trade | ₹8.95 Cr | ₹15.82 Cr | ₹25.69 Cr | ₹14.27 Cr | ₹10.85 Cr | ₹15.55 Cr | ₹16.57 Cr | ₹12.45 Cr | ₹14.34 Cr | ₹12 Cr | ₹15.66 Cr | ₹16.06 Cr |
| Changes in Inventories | -₹18.06 Cr | -₹14.07 Cr | -₹39.25 Cr | ₹2.52 Cr | -₹44.09 Cr | ₹5.03 Cr | ₹4.62 Cr | ₹9.53 Cr | -₹16.68 Cr | ₹10.41 Cr | -₹1.84 Cr | ₹39.44 Lakh |
| Employee Benefit Expense | ₹38.14 Cr | ₹40.09 Cr | ₹37.45 Cr | ₹36 Cr | ₹35.57 Cr | ₹33.96 Cr | ₹28.47 Cr | ₹29.05 Cr | ₹29.6 Cr | ₹30.6 Cr | ₹26.78 Cr | ₹23.37 Cr |
| Finance Costs | ₹9.44 Cr | ₹8.36 Cr | ₹9.58 Cr | ₹9.23 Cr | ₹8.4 Cr | ₹4.91 Cr | ₹5.18 Cr | ₹4.62 Cr | ₹3.65 Cr | ₹3.18 Cr | ₹4.46 Cr | ₹4.07 Cr |
| Depreciation & Amortisation | ₹7.65 Cr | ₹7.69 Cr | ₹7.77 Cr | ₹7.72 Cr | ₹7.84 Cr | ₹4.62 Cr | ₹4.3 Cr | ₹4.31 Cr | ₹4.34 Cr | ₹4.14 Cr | ₹4.3 Cr | ₹4.24 Cr |
| Other Expenses | ₹52.83 Cr | ₹53.88 Cr | ₹57.27 Cr | ₹53.27 Cr | ₹53.14 Cr | ₹45.73 Cr | ₹40.95 Cr | ₹43.24 Cr | ₹42.55 Cr | ₹39.38 Cr | ₹39.62 Cr | ₹39.33 Cr |
| Total Expenses | ₹223.23 Cr | ₹210.84 Cr | ₹211.98 Cr | ₹211.53 Cr | ₹194.62 Cr | ₹183.38 Cr | ₹175.03 Cr | ₹175.96 Cr | ₹168.76 Cr | ₹172.64 Cr | ₹184.26 Cr | ₹167.85 Cr |
| Profit Before Exceptional Items & Tax | ₹27.63 Cr | ₹21.05 Cr | ₹20.53 Cr | ₹16.28 Cr | ₹10.78 Cr | ₹26.28 Cr | ₹29.26 Cr | ₹28.11 Cr | ₹27.12 Cr | ₹29.56 Cr | ₹30.95 Cr | ₹28.05 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹27.63 Cr | ₹21.05 Cr | ₹20.53 Cr | ₹16.28 Cr | ₹10.78 Cr | ₹26.28 Cr | ₹29.26 Cr | ₹28.11 Cr | ₹27.12 Cr | ₹29.56 Cr | ₹30.95 Cr | ₹28.05 Cr |
| Total Tax Expense | ₹7.05 Cr | ₹5.49 Cr | ₹5.59 Cr | ₹4.2 Cr | ₹2.81 Cr | ₹6.96 Cr | ₹7.49 Cr | ₹7.25 Cr | ₹7.07 Cr | ₹7.3 Cr | ₹7.74 Cr | ₹7.43 Cr |
| Net Profit | ₹20.57 Cr | ₹15.56 Cr | ₹14.94 Cr | ₹12.07 Cr | ₹7.97 Cr | ₹19.32 Cr | ₹21.78 Cr | ₹20.86 Cr | ₹20.05 Cr | ₹22.26 Cr | ₹23.21 Cr | ₹20.62 Cr |
| Other Comprehensive Income | ₹49.93 Lakh | ₹0 | ₹0 | ₹0 | -₹12.77 Lakh | ₹0 | ₹0 | ₹0 | -₹40.39 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹21.07 Cr | ₹15.56 Cr | ₹14.94 Cr | ₹12.07 Cr | ₹7.85 Cr | ₹19.32 Cr | ₹21.78 Cr | ₹20.86 Cr | ₹19.64 Cr | ₹22.26 Cr | ₹23.21 Cr | ₹20.62 Cr |
| EBITDA (computed) | ₹44.71 Cr | ₹37.1 Cr | ₹37.89 Cr | ₹33.23 Cr | ₹27.02 Cr | ₹35.81 Cr | ₹38.74 Cr | ₹37.04 Cr | ₹35.11 Cr | ₹36.88 Cr | ₹39.7 Cr | ₹36.36 Cr |
| Basic EPS | ₹2.05 | ₹1.55 | ₹1.49 | ₹1.20 | ₹0.80 | ₹1.93 | ₹2.17 | ₹2.08 | ₹2.00 | ₹2.23 | ₹2.39 | ₹2.13 |
| Diluted EPS | ₹2.05 | ₹1.55 | ₹1.49 | ₹1.20 | ₹0.80 | ₹1.93 | ₹2.17 | ₹2.08 | ₹2.00 | ₹2.23 | ₹2.39 | ₹2.13 |
Shareholding Pattern of Gufic Biosciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 72.50%, foreign institutional investors hold 0.42%, domestic institutional investors hold 3.83%, retail and other public shareholders hold 23.24% of Gufic Biosciences Limited. The company had 29,223 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 72.50% | 72.50% | 72.50% | 72.51% | 72.51% | 72.51% |
| Public | 27.50% | 27.50% | 27.50% | 27.49% | 27.49% | 27.49% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.50% | 72.51% | 72.51% | 75.00% | 75.48% | 65.75% | 65.75% | 65.75% | 65.73% | 69.98% | 69.98% |
| Public | 27.50% | 27.49% | 27.49% | 25.00% | 24.52% | 34.25% | 34.25% | 34.25% | 34.27% | 30.02% | 30.02% |
| Promoter change (YoY, %pts) | -0.01 | +0.00 | -2.49 | -0.48 | +9.73 | +0.00 | +0.00 | +0.02 | -4.25 | +0.00 | - |
Board & Governance of Gufic Biosciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Gufic Biosciences Limited has 6 directors - 3 independent and 3 executive. The board is chaired by JAYESH PANNALAL CHOKSI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| JAYESH PANNALAL CHOKSI | Executive Director · MD · Chairperson | 2009-08-31 | 1 |
| PRANAV JAYESH CHOKSI | Executive Director · CEO | 2004-06-25 | 1 |
| PANKAJ JAYAKUMAR GANDHI | Executive Director | 2013-08-01 | 1 |
| ANU SANJIV AURORA | Non-Executive - Independent Director | 2019-12-23 | 1 |
| KAMAL KISHORE SETH | Non-Executive - Independent Director | 2024-06-27 | 2 |
| AKSHYA KUMAR MAHAPATRA | Non-Executive - Independent Director | 2024-11-14 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | KAMAL KISHORE SETH (Chairperson), ANU SANJIV AURORA, JAYESH PANNALAL CHOKSI, AKSHYA KUMAR MAHAPATRA |
| Nomination and remuneration committee | ANU SANJIV AURORA (Chairperson), KAMAL KISHORE SETH, AKSHYA KUMAR MAHAPATRA |
| Stakeholders Relationship Committee | ANU SANJIV AURORA (Chairperson), JAYESH PANNALAL CHOKSI, PRANAV JAYESH CHOKSI |
| Risk Management Committee | JAYESH PANNALAL CHOKSI (Chairperson), PRANAV JAYESH CHOKSI, ANU SANJIV AURORA, NAGESH YARRABATHINA, DEVKINANDAN B. ROONGHTA |
| Corporate Social Responsibility Committee | JAYESH PANNALAL CHOKSI (Chairperson), PRANAV JAYESH CHOKSI, ANU SANJIV AURORA |
Group Structure of Gufic Biosciences Limited
Gufic Biosciences Limited has 1 subsidiary company. This group structure data is as of FY 2025. The corporate group structure reflects Gufic Biosciences Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Gufic Prime Private Limited | U46497MP2023PTC068618 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Gufic Biosciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Sep 2025 | Others | ₹15.3 Lakh | Open |
| 31 Jan 2025 | Others | ₹29.5 Lakh | Open |
| 31 Jan 2025 | Others | ₹29.5 Lakh | Open |
| 18 Jun 2024 | Others | ₹80 Cr | Open |
| 31 May 2024 | Others | ₹10 Lakh | Open |
Total charge records: 54 View all charges
Employees and EPFO Compliance at Gufic Biosciences Limited
Gufic Biosciences Limited has a workforce of 1,362 employees as of Sep 23, 2025.
Employee Count & EPFO Data of Gufic Biosciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Gufic Biosciences Limited
GSTIN & GST Filing Data of Gufic Biosciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Gufic Biosciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Gufic Biosciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Gufic Biosciences Limited
MSME Payment Delays by Gufic Biosciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Gufic Biosciences Limited
Subsidiaries & Group Companies of Gufic Biosciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Gufic Biosciences Limited with ownership details.
MCA Filings & Documents of Gufic Biosciences Limited
MCA Filings & Documents of Gufic Biosciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Gufic Biosciences Limited
Recent News on Gufic Biosciences Limited
Frequently Asked Questions about Gufic Biosciences Limited
Gufic Biosciences Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 23 July 1984 (42+ years old) and is registered under CIN L24100MH1984PLC033519. Listed on BSE: 509079 and NSE: GUFICBIO. The company has 1,362 employees.
Gufic Biosciences Limited reported revenue of ₹823.43 Cr for FY 2025 (up 2.00% YoY).
The current directors of Gufic Biosciences Limited are:
- Akshya Kumar Mahapatra
- Pranav Jayesh Choksi
- Pankaj Jayakumar Gandhi
- Jayesh Pannalal Choksi
- Kamal Kishore Seth
- Anu Sanjiv Aurora
- Devki Nandan Banwarilal Roonghta
- Ami Shah
The primary industry of Gufic Biosciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Gufic Biosciences Limited is listed on both BSE (code: 509079) and NSE (symbol: GUFICBIO).
Gufic Biosciences Limited can be reached at the registered office: Shop – 37 First Floor Kamala Bhavan Ii S Nityanand Road Andheri East, Mumbai, Maharashtra, India – 400069, or through the website gufic.com.